Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho Licenses Anti-Allergy Drug from Faes Farma in Japan
July 26, 2012
- Sandoz Launches Generic Claritin
July 26, 2012
- MTPC Launches Low-dose Anxiolytic Depas on July 24
July 26, 2012
- MSD Changes Name of Aroglycem to Diazoxide to Prevent Medication Errors
July 25, 2012
- MSD to File NDA for Odanacatib in Japan in First Half of 2013
July 25, 2012
- New Research Lab for Plasma Fractionation Business to Be Set Up in Kobe
July 25, 2012
- Nippon Kayaku to Increase Production of Carboplatin Due to Sandoz’s Shipment Suspension
July 25, 2012
- Meiji Seika Pharma Discontinues Development of Schizophrenia Treatment AM-831
July 24, 2012
- AnGes MG to Conduct Domestic PI/II Trials of Collategene for Lymphedema in Fall
July 24, 2012
- IBL-Japan Concludes Codevelopment Agreement with IBL International for Diagnostic for Alzheimer Disease
July 24, 2012
- Kyowa Kirin Revises Business Forecast Upward on Steady Sales of Nesp
July 24, 2012
- Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
- Combination Drug Containing JR-051 to Be Developed: JCR
July 23, 2012
- Azilva Ranked No. 1 in Both HP, GP Markets for 2 Straight Months: Rep Track Survey
July 23, 2012
- Patent Cliff for Kipres Looms; Will Kyorin Continue to Stand Alone in Respiratory Disease Field?
July 23, 2012
- HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
- Aricept Successor BACE Inhibitor Reduced Aβ in PI Studies: Eisai
July 20, 2012
- Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
- Sandoz Initiates Voluntary Recall of Carboplatin, Shipment Suspended
July 20, 2012
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…